Treatment of Crohn's disease with Adalimumab in pregnancy – a case report

Aims: The fully recombinant human IgG1 antibody adalimumab (Humira, Abbott Laboratories) became an alternative option for treatment of Inflammatory bowel disease. Since many young women in childbearing age are affected by Crohn's disease (CD), it is important to investigate the influences and effects of TNF-α-antibodies regarding the fetal safety. Although infliximab seems to be a safe drug given in conception and pregnancy (Schnitzler F. et al.; DDW 2007), the number of data concerning the effects on conception and gravidity are scarce. Therefore we report of a case of pregnancy and the appliance of adalimumab…